Cochrane · systematic review · CD010968
alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis
Zhang, J, Shi, S, Zhang, Y, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Multiple Sclerosis and Rare Diseases of the CNSAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
13
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 15.4%Low 8 · 61.5%Moderate 3 · 23.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Alemtuzumab 12 mg compared to interferon beta 1a for relapsing‐remitting multiple sclerosis
Population: patients with relapsing‐remitting multiple sclerosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing at least one relapse Alemtuzumab 12 mg vs interferon beta 1a | RR 0.6 [0.52, 0.7] | 3 studies · 1414 participants | Moderate Downgraded: risk of bias |
Number of participants whose disability worsened Alemtuzumab 12 mg vs interferon beta 1a | RR 0.6 [0.45, 0.79] | 3 studies · 1414 participants | Low Downgraded: risk of bias |
Number of participants with at least one adverse event Alemtuzumab 12 mg vs interferon beta 1a | RR 1.03 [0.98, 1.08] | 3 studies · 1415 participants | Low Downgraded: risk of bias |
Number of participants with serious adverse events Alemtuzumab 12 mg vs interferon beta 1a | RR 1.03 [0.82, 1.29] | 3 studies · 1415 participants | Moderate Downgraded: risk of bias |
Mean Expanded Disability Status Scale score change from baseline Alemtuzumab 12 mg vs interferon beta 1a | no estimate extracted | 3 studies · 1414 participants | Low Downgraded: risk of bias |
Number of participants with new T2‐hyperintense lesions on magnetic resonance imaging Alemtuzumab 12 mg vs interferon beta 1a | RR 0.75 [0.61, 0.93] | 2 studies · 1125 participants | Low Downgraded: risk of bias |
Number of participants experiencing treatment discontinuation caused by adverse events Alemtuzumab 12 mg vs interferon beta 1a | RR 0.33 [0.19, 0.56] | 3 studies · 1414 participants | Low Downgraded: risk of bias |
Alemtuzumab 24 mg compared to interferon beta 1a for relapsing‐remitting multiple sclerosis
Population: patients with relapsing‐remitting multiple sclerosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing at least one relapse Alemtuzumab 24 mg vs interferon beta 1a | RR 0.38 [0.23, 0.62] | 1 study · 221 participants | Low Downgraded: risk of bias |
Number of participants whose disability worsened Alemtuzumab 24 mg vs interferon beta 1a | RR 0.42 [0.21, 0.84] | 1 study · 221 participants | Low Downgraded: risk of bias |
Number of participants with at least one adverse event Alemtuzumab 24 mg vs interferon beta 1a | RR 1.02 [0.96, 1.08] | 2 studies · 578 participants | Low Downgraded: risk of bias |
Number of participants with serious adverse events Alemtuzumab 24 mg vs interferon beta 1a | RR 0.95 [0.7, 1.31] | 2 studies · 578 participants | Moderate Downgraded: risk of bias |
Mean Expanded Disability Status Scale score change from baseline Alemtuzumab 24 mg vs interferon beta 1a | no estimate extracted | 1 study · 221 participants | Very low Downgraded: risk of bias |
Number of participants experiencing treatment discontinuation caused by adverse events Alemtuzumab 24 mg vs interferon beta 1a | RR 0.34 [0.1, 1.16] | 2 studies · 593 participants | Very low Downgraded: risk of bias |